Guo Shuaishuai

Beijing University of Traditional Chinese Medicine

Abstract：

Ulcerative colitis (UC) represents a chronic idiopathic inflammatory bowel disease that imposes substantial burdens on clinical practice and public health. Intestinal mucosal immune disorder serves as a core pathological basis for the initiation and progression of UC, and sustained regulation of mucosal immunity represents a key direction for long-term disease management. Anti-inflammatory drugs remain the mainstream strategy for maintenance of remission in UC, and these agents exert favorable effects on stabilizing mucosal immune balance, reducing inflammatory responses, protecting mucosal structure, and prolonging remission duration. This study systematically summarizes the characteristics of intestinal mucosal immune disorders in UC, clarifies the regulatory mechanisms of mainstream anti-inflammatory drugs on mucosal immunity, analyzes clinical application schemes and optimization directions of maintenance therapy, and explores strategies to improve therapeutic stability and mucosal repair capacity. The aim of this work is to provide theoretical support and practical references for standardized, individualized, and long-term management of UC, and to promote further improvement in the quality of maintenance treatment and long‑term outcomes of patients.

Key Words：

ulcerative colitis; intestinal mucosal immunity; anti-inflammatory drugs